Lee's moving forward with dry eye candidate

Lee's said it is accelerating development of RGN-259 as a result of the the launch of its China Ophthalmology Focus Ltd. subsidiary and its new ophthalmic manufacturing facilities. The company is developing RGN-259 in China, Taiwan, Macau and Hong Kong to treat persistent corneal disorders such as dry eye syndrome and neurotrophic keratitis.

Lee's Pharmaceutical Holdings Ltd. (HKSE:0950) in-licensed the eye drop from RegeneRx Biopharmaceuticals Inc. (OTCQB:RGRX) in 2012...